| 摘要 |
<p>The invention provides anti-FRA antibodies with novel N-linked neutral glycan profiles in that the relative amounts of one or more neutral glycans are increased or decreased compared to anti- FRA antibodies produced under reference cell culture conditions. The invention further provides anti-FRA antibodies with altered binding to FRA, altered antibody-dependent cellular cytotoxicity (ADCC) and/or altered rate and/or efficiency of internalization in a cell expressing FRA. In related aspects, the invention provides cell cultures comprising an anti-FRA antibody of the invention, a cell isolated from such a culture, kits and compositions comprising an anti-FRA antibody of the invention, methods of producing an anti-FRA antibody of the invention and diagnostic and therapeutic uses of an anti-FRA antibody of the invention.</p> |
| 申请人 |
MORPHOTEK, INC.;SASS, PHILIP M.;NICOLAIDES, NICHOLAS;GRASSO, LUIGI;ROUTHIER, ERIC;GU, WEI;YOUNG, JASON;YAO, JUN |
发明人 |
SASS, PHILIP M.;NICOLAIDES, NICHOLAS;GRASSO, LUIGI;ROUTHIER, ERIC;GU, WEI;YOUNG, JASON;YAO, JUN |
